News

Show
news from

Quell Therapeutics and Cellistic™ enter a strategic collaboration to develop an iPSC-derived allogeneic T-regulatory (Treg) cell therapy platform

Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform

Quell Therapeutics Granted CTA Approval to Begin First Clinical Trial with a Multi-modular Engineered Treg Cell Therapy

Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Quell Therapeutics Appoints Dominik Hartl, M.D., as Chief Medical Officer

Quell Therapeutics Enters a Collaborative Research Agreement with the University of Sheffield

Load more

Search